AQST
Aquestive Therapeutics Inc.
$5.17
-$0.50(-8.82%)
45
Overall
--
Value
45
Tech
--
Quality
Market Cap
$565.43M
Volume
4.54M
52W Range
$2.12 - $6.00
Target Price
$8.78
Order:
Income Statement
| Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | $67.4M | $52.6M | $45.8M | $50.8M | $47.7M | $50.6M | $57.6M | ||
| Total Revenue | $67.4M | $52.6M | $45.8M | $50.8M | $47.7M | $50.6M | $57.6M | ||
| COST OF GOODS SOLD | |||||||||
| Cost of Revenue | -- | $-20.4M | $-13.0M | $15.0M | $19.4M | $20.8M | $17.9M | ||
| GROSS PROFIT | |||||||||
| Gross Profit | $67.4M | $32.2M | $45.8M | $35.8M | $28.3M | $29.8M | $39.7M | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $-116.4M | $84.9M | $88.7M | $85.5M | $70.4M | $45.8M | $75.9M | ||
| Research & Development | $23.1M | $20.6M | $19.9M | $17.0M | $17.5M | $13.1M | $20.3M | ||
| Research Expense | $23.1M | $20.6M | $19.9M | $17.0M | $17.5M | $13.1M | $20.3M | ||
| Selling, General & Administrative | $72.3M | $64.3M | $55.9M | $53.5M | $52.9M | $31.8M | $50.2M | ||
| Selling & Marketing Expenses | $72.3M | $64.3M | $55.9M | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-1.4M | $-1.6M | $55.9M | $53.5M | $52.9M | $31.8M | $50.2M | ||
| Salaries & Wages | $-29.9M | $-7.1M | $-6.6M | -- | -- | $2.7M | $7.1M | ||
| Depreciation & Amortization | $-3.2M | $-2.9M | $3.4M | $2.9M | $2.3M | $1.2M | $640.0K | ||
| Depreciation & Amortization | $-3.2M | $-2.9M | $2.0M | $2.9M | $2.3M | $1.2M | $640.0K | ||
| Amortization | $-1.7M | $-2.0M | $51.0K | $51.0K | $331.0K | $2.1M | $10.8M | ||
| Other Operating Expenses | $21.0M | $-66.0K | $-13.0M | $-15.0M | $1.8M | $905.0K | $5.5M | ||
| OPERATING INCOME | |||||||||
| Operating income | $-48.9M | $-52.7M | $-42.9M | $-34.7M | $-42.1M | $-15.1M | $-30.8M | ||
| EBITDA | $-48.7M | $-52.1M | $-39.3M | $-45.1M | $-39.6M | $1.2M | $-32.7M | ||
| NON-OPERATING ITEMS | |||||||||
| Interest Expense (Non-Operating) | $7.7M | $9.3M | $13.0M | $22.5M | $12.4M | $7.5M | -- | ||
| Intinc | $552.0K | $636.0K | $132.0K | $423.0K | $99.0K | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-7.2M | $-8.7M | $-10.9M | $-9.6M | $12.3M | $-8.9M | -- | ||
| Other Income/Expense | $5.3M | $4.9M | $447.0K | $13.8M | -- | $1.4M | $-300.0K | ||
| Other Special Charges | $-5.3M | $-4.9M | $-165.0K | $-13.8M | -- | $-1.4M | $300.0K | ||
| SPECIAL ITEMS | |||||||||
| Restructring And Mn A Income | $-130.0K | $-144.0K | $-165.0K | -- | -- | -- | -- | ||
| Special Income Charges | $130.0K | $144.0K | $165.0K | -- | -- | -- | -- | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | $216.0K | -- | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $-53.7M | $-56.9M | $-42.8M | $-48.1M | $-42.0M | $-7.6M | $-44.2M | ||
| Pre-Tax Income | $-61.4M | $-66.2M | $-55.8M | $-70.5M | $-54.4M | $-7.6M | $-44.2M | ||
| INCOME TAX | |||||||||
| Tax Provision | -- | -- | -- | -- | -- | $245.0K | $-14.0K | ||
| NET INCOME | |||||||||
| Net Income | $-61.4M | $-66.2M | $-55.8M | $-70.5M | $-54.4M | $-7.9M | $-44.1M | ||
| Net Income (Continuing Operations) | $-61.4M | $-66.2M | $-55.8M | $-70.5M | $-54.4M | $-7.9M | $-44.1M | ||
| Net Income (Discontinued Operations) | $-61.4M | $-66.2M | $-55.8M | $-70.5M | $-54.4M | $-7.9M | $-44.1M | ||
| Net Income (Common Stockholders) | $-61.4M | $-66.2M | $-27.9M | $-70.5M | $-54.4M | $-7.9M | $-44.1M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-44.2M | ||
| TOTALS | |||||||||
| Total Expenses | $-116.4M | $64.6M | $64.8M | $85.5M | $89.7M | $66.6M | $93.8M | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $20.7M | $25.4M | $33.7M | $38.1M | $48.7M | $61.3M | $86.7M | ||
| Average Shares Outstanding (Diluted) | $20.7M | $25.4M | $33.6M | $38.1M | $48.7M | $61.3M | $86.7M | ||
| Shares Outstanding | $25.0M | $33.6M | $36.2M | $41.5M | $55.9M | $73.3M | $98.9M | ||
| Basic EPS | -- | -- | -- | $-1.85 | $-1.12 | $-0.13 | $-0.51 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-1.85 | $-1.12 | $-0.13 | $-0.51 | ||
| Diluted EPS | $-2.96 | $-2.61 | $-1.66 | $-1.85 | $-1.12 | $-0.13 | $-0.51 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-1.85 | $-1.12 | $-0.13 | $-0.51 | ||
| OTHER METRICS | |||||||||
| Other Gand A | $-1.4M | $-1.6M | $55.9M | $53.5M | $52.9M | $31.8M | $50.2M | ||
| Other Write Off | $-50.0K | -- | $282.0K | -- | -- | -- | -- | ||
| Rent And Landing Fees | $-1.4M | $-1.6M | -- | -- | -- | -- | -- | ||
| Selling Expense | $72.3M | $64.3M | $55.9M | -- | -- | -- | -- | ||
| Restruct | $-130.0K | $-144.0K | $-165.0K | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AQST | $5.17 | -8.8% | 4.54M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Aquestive Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW